Vaccines & Disease · Measles

Measles disease & vaccine quick facts

3 min read
01

Measles (Rubeola)

  • Measles (rubeola) is a highly contagious respiratory disease spread by coughing, sneezing, or simply being in close contact with an infected individual. The disease can be spread even when the rash is not visible.1 Measles tends to be more severe in children under 5 and adults over 20.2
  • Initial measles symptoms include fever, cough, runny nose, red irritated eyes, and sore throat with tiny white spots on the cheeks inside the mouth (Koplik spots). These symptoms generally last 2-4 days and are followed by the signature itchy red rash which appears on the body around the fourth or fifth day. The rash usually begins on the head and moves down the body to the feet.3
  • After coming in contact with someone infected with measles, the incubation period to onset of the rash is between 7 and 21 days, with an average of 14 days. The period leading up to the appearance of the rash is characterized by a rising fever that peaks at 103-105 degrees F. Complications of measles can include bronchitis, diarrhea, ear infections, pneumonia, seizures, encephalitis and death.4
  • Studies have concluded that vitamin A reduces the risk of measles complications and death. Children with vitamin A deficiency, especially those living in underdeveloped countries, are at a higher risk of developing complications.5 Receiving measles immune globulin, a product made from human blood containing high levels of measles antibodies, within 6 days of exposure can mediate the severity of the illness.6
  • In 1960, three years before the first measles vaccine became available in the U.S., there were approximately 442,000 reported measles cases and 380 related deaths,78 among the 3.5 to 5 million Americans who were likely infected with measles.910 Historically, measles deaths have been reported at a rate of 1 in 10,000 cases.1112 Measles-associated deaths are rare in the U.S. and the last reported death occurred in 2015.13 Globally, 95 percent of measles deaths occur in developing countries, where the disease is one of the leading causes of death among young children.14
02

Measles Vaccine

  • There are three measles vaccines currently in use in the United States. Two vaccines, MMRII15 and PRIORIX,16 are combination measles-mumps-rubella (MMR) live virus vaccines. The third vaccine, ProQuad, is a combination measles-mumps-rubella-varicella (MMR-V) live virus vaccine.17 Both MMRII and ProQuad are manufactured and distributed by Merck, while PRIORIX is manufactured and distributed by GlaxoSmithKline.18 The CDC recommends children receive the first dose of MMR vaccine between 12 and 15 months, and the second dose between 4 and 6 years.19
  • Mild side effects such as redness, rash or pain at the injection site, along with fever and swelling of the glands in the neck or cheeks have been reported following MMR or MMR-V vaccination. More serious side effects following vaccination include seizures, thrombocytopenia, pneumonia, meningitis, encephalitis, full body rash, brain damage, permanent loss of hearing, coma, and death.2021
  • As of January 2, 2026, there have been 118,645 reports of measles-vaccine reactions, hospitalizations, injuries, and deaths following measles vaccinations made to the federal Vaccine Adverse Events Reporting System (VAERS), including 580 related deaths, 9,203 hospitalizations, and 2,251 related disabilities. Approximately 50 percent of those adverse events occurred in children under three years of age.
  • As of December 1, 2025, there have been 1,390 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following measles vaccination, for 87 deaths and 1,303 serious injuries.
  • Medical studies report that vaccinated persons can get measles because they either do not respond to the vaccine or the vaccine’s efficacy wanes over time.2223242526 Vaccinated mothers do not transfer long-lasting maternal antibodies to their infants which would protect them for the first few months of life.272829
Food & Drug Administration (FDA)

IMPORTANT NOTE: NVIC encourages you to become fully informed about Measles and the Measles vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.

References
  1. 1US Centers for Disease Control and Prevention. Transmission of Measles. Nov. 5, 2020.
  2. 2US Centers for Disease Control and Prevention. Complications of Measles. Nov. 5, 2020.
  3. 3US Centers for Disease Control and Prevention. Signs and Symptoms. Nov. 5, 2020.
  4. 4Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Measles. 13th ed. Centers for Disease Control (CDC) Aug. 18, 2021.
  5. 5D'Souza RM, D'Souza R. Vitamin A for treating measles in children. Cochrane Database Syst Rev. Apr. 23, 2002.
  6. 6US Centers for Disease Control and Prevention. Post-exposure Prophylaxis. Nov. 5, 2020.
  7. 7Public Health Service. Reported incidence of notifiable diseases in the United States 1962. MMWR 1963; 11(53): 1-29.
  8. 8National Center for Health Statistics. Death Rates for Selected Causes by 10-Year Age Groups, Race, and Sex: Death Registration States, 1900-32, and United States, 1933-98. National Vital Statistics System. Nov. 6, 2015.
  9. 9US Centers for Disease Control and Prevention. Measles, Mumps and Rubella – Vaccine Use and Strategies for Elimination of Measles, Rubella and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR May 22, 1998.
  10. 10Wood DJ, Brunell PA. Measles Control in the United States: Problems of the Past and Challenges for the Future. Clin Microbiol Rev 1995; 8(2): 260-267.
  11. 11US National Communicable Disease Center. Immunization against disease 1966-67. Bureau of Disease Prevention and Environmental Control.
  12. 12Public Health Service. SUPPLEMENT – Collected Recommendations of the Public Health Service Advisory Committee on Immunization Practices. MMWR Oct. 25, 1969; 18(43):1-31.
  13. 13Adams DA, Thomas KR, Jajosky RA, et al. Summary of Notifiable Infectious Diseases and Conditions — United States, 2015. MMWR Aug. 11, 2017; 64(53);1–143.
  14. 14World Health Organization. Measles. Dec. 5, 2019.
  15. 15Merck, Sharp & Dohme Corp. Package Insert – Measles, Mumps and Rubella Virus Vaccine, Live. U.S. Food and Drug Administration Dec. 14, 2020.
  16. 16GlaxoSmithKline. PRIORIX. U.S. Food and Drug Administration July 1, 2022.
  17. 17Merck Sharpe & Dohme Corp. Package Insert – Refrigerator-Stable Formulation – ProQuad. U.S. Food and Drug Administration Apr. 16, 2021.
  18. 18US Food and Drug Administration. Vaccines Licensed for Use in the United States. July 5, 2022.
  19. 19McLean HQ. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Jun. 14, 2013.
  20. 20US Centers for Disease Control and Prevention. MMR (Measles, Mumps, & Rubella) VIS. Aug. 6, 2021.
  21. 21US Centers for Disease Control and Prevention. MMRV (Measles, Mumps, Rubella & Varicella) VIS. Aug. 6, 2021.
  22. 22Kang HJ, Han YW, Kim SJ et al. An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine Jul 24, 2017; 35(33):4126-4132.
  23. 23Hahné SJ, Nic Lochlainn LM, van Burgel ND et al. Measles Outbreak Among Previously Immunized Healthcare Workers, the Netherlands, 2014. J Infect Dis Dec 15, 2016; 214(12):1980-1986.
  24. 24Rosen JB, Rota JS, Hickman CJ et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin Infect Dis May 2014; 58(9):1205-10.
  25. 25Fiebelkorn AP, Coleman LA, Belongia EA et al. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults. J Infect Dis Apr 1, 2016; 213(7):1115-23.
  26. 26Mizumoto K, Kobayashi T, Chowell G. Transmission potential of modified measles during an outbreak, Japan, March‒May 2018. Euro Surveill May 2018.
  27. 27Waaijenborg S, Hahné SJ, Mollema L et al. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. J Infect Dis Jul 2013; 208(1):10-6.
  28. 28Zhao H, Lu P-S, Hu Y. Low Titers of Measles Antibody in Mothers Whose Infants Suffered from Measles before Eligible Age for Measles Vaccination. Virology.
  29. 29Gans HA, Maldonado YA. Loss of passively acquired maternal antibodies in highly vaccinated populations: an emerging need to define the ontogeny of infant immune responses. J Infect Dis Jul 2013; 208(1):1-3.
Select disease / vaccine